FDA, European Approaches To Stryker OP-1 Data Produce Conflicting Results
This article was originally published in The Gray Sheet
Executive Summary
FDA's "non-approvable" letter for Stryker's OP-1 bone growth factor PMA for treating nonunion fractures was prompted by insufficient radiographic data, as opposed to clinical outcomes.